Last reviewed · How we verify
Nykode Therapeutics ASA — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
1 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Atezolizumab Injection [Tecentriq] | Atezolizumab Injection [Tecentriq] | marketed | PD-L1 inhibitor | PD-L1 | Oncology |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ascletis Pharmaceuticals Co., Ltd. · 1 shared drug class
- Assistance Publique Hopitaux De Marseille · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Biocad · 1 shared drug class
- CStone Pharmaceuticals · 1 shared drug class
- Celltrion · 1 shared drug class
- Clovis Oncology, Inc. · 1 shared drug class
- 3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Nykode Therapeutics ASA:
- Nykode Therapeutics ASA pipeline updates — RSS
- Nykode Therapeutics ASA pipeline updates — Atom
- Nykode Therapeutics ASA pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Nykode Therapeutics ASA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nykode-therapeutics-asa. Accessed 2026-05-16.